US filing analysis
Sorted by SEC acceptance time (filing date when unavailable). Page 1 · 30 shown · up to 30 per page
MSI
The company said its net sales for Q3 2026 were $3.4 billion, compared with $3.0 billion for Q3 2025, and its operating earnings were $777 million, compared with $770 million for Q3 2025.
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Motorola SolutionsMSI$520.21-0.33%
ATO
The company said Kim R. Cocklin will retire from the board and as Chairman at the 2027 Annual Meeting. He intends to continue serving as Chairman through the 2027 Annual Meeting, the company said.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Atmos EnergyATO$168.28-0.24%
MLM
Martin Marietta said it acquired all of the equity in Lhoist North America, Inc. on August 21, 2026, paying a total of $12,887 million, consisting of $7,028 million in cash and 10,953,543 newly issued shares valued at $5,859 million.
US filing analysisUS8-K/A · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Martin Marietta MaterialsMLM$500.74-1.19%
ORCL
The company said it entered into an underwriting agreement with BofA Securities, Inc., as representative of the underwriters, on November 2, 2026 to issue and sell 86,206,897 shares of common stock, and that the offering closed on November 4, 2026.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
OracleORCL$102.04-7.71%
CF
The company said net earnings attributable to common stockholders for the first 9 months of 2026 were $1.78 billion ($11.60 per diluted share), and adjusted EBITDA was $3.01 billion, including a gain of about $170 million from a litigation settlement. Net earnings for Q3 were $436 million, and adjusted EBITDA was $833 million.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
CF IndustriesCF$115.53-0.20%
ATO
The company reported fiscal 2026 diluted earnings per share of $8.49 on net income of $1.4 billion.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Atmos EnergyATO$168.28-0.24%
STE
The company said revenue for Q2 rose to $1,588.6 million from $1,460.3 million a year earlier, and net income attributable to shareholders was $213.7 million ($2.19 per diluted share).
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
STERISSTE$255.76+0.39%
GL
Globe Life said net income for the nine months ended September 30, 2026 totaled $919 million, up 3% from $895 million in the prior-year period, and net operating income (non-GAAP) was $937 million, up 1% from $925 million.
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Globe LifeGL$151.65-1.26%
APA
The company said net income attributable to common stock for Q3 2026 was $698 million ($2.00 per diluted share). Adjusted for certain items, earnings for the Q3 were $676 million ($1.94 per diluted share).
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
APAAPA$45.03+0.92%
HPQ
HP said the Board appointed Emma Walmsley as Chief Executive Officer on November 4, 2026, effective January 4, 2027. Bruce Broussard, the current Interim Chief Executive Officer, will step down from that role at the end of the day on January 3, 2027 and will become Chair of the Board effective January 4, 2027.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
HPHPQ$27.96+0.50%
ALB
Albemarle said net sales for Q3 2026 were $1.6 billion, up 19% from a year earlier, mainly due to higher pricing, which the company cited as a 39% increase. The company also said adjusted EBITDA improved 186% year over year.
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
AlbemarleALB$79.7-3.89%
EW
Edwards Lifesciences said net sales for the first 9 months of 2026 were $5.1 billion, an increase of $607.1 million from the same period of 2025, driven mainly by sales of its TAVR and TMTT products.
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Edwards LifesciencesEW$101.85-1.95%
GWW
The company said net sales for the 3 months ended September 30, 2026 were $5,181 million, up $524 million or 11%, and that on a daily, organic constant currency basis, net sales rose 15%.
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
W.W. GraingerGWW$1,357.35-4.67%
MET
The company said net income for Q3 2026 was $2.4 billion ($3.67 per share), up 187% from a year earlier, and adjusted earnings were $1.8 billion ($2.78 per share), up 12%.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
MetLifeMET$95.67-1.98%
EW
The company said net sales for Q3 2026 rose to $1,715.5 million, up 10.5% from $1,553.1 million a year earlier (11.2% on a constant currency basis). TAVR sales grew 8.0%, and TMTT sales grew 44.3%.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Edwards LifesciencesEW$101.85-1.95%
WAB
Wabtec said it completed a public offering of $500,000,000 aggregate principal amount of its 5.900% Senior Notes due 2037 on November 4, 2026. The offering was made under the company's existing shelf registration statement on Form S-3 filed with the SEC on October 21, 2026.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
WabtecWAB$269.31-4.07%
AFL
The company said net earnings for Q3 2026 fell to $303 million ($0.61 per diluted share) from $1.6 billion ($3.08 per share) a year earlier, and adjusted earnings decreased 8.5% to $1.2 billion.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
AflacAFL$124.32-0.35%
ALB
Albemarle said net sales for Q3 2026 were $1,553.1 million ($1,307.8 million in the prior-year quarter), up 18.8%, and adjusted EBITDA was $645.5 million ($225.6 million in the prior-year quarter), up 186.1%.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
AlbemarleALB$79.7-3.89%
ALL
The company said net income applicable to common shareholders decreased $1.67 billion to $2.05 billion in Q3 2026 compared with the same quarter of the prior year, and rose $1.36 billion to $7.72 billion for the 9 months ended in 2026.
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
AllstateALL$267+0.09%
TPL
The company said total revenues for the three months ended September 30, 2026 were $273.4 million (compared with $203.1 million a year earlier), and net income was $167.4 million (compared with $121.2 million). Total operating expenses were $65.6 million (compared with $54.0 million).
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Texas Pacific LandTPL$267.44-3.70%
AMCR
The company said net sales for the 3-month period ended September 30, 2026 were $6,129 million, up 7% from $5,745 million a year earlier. It said net income attributable to the parent was $242 million (versus $262 million a year earlier) and diluted EPS was $0.52 (versus $0.57 a year earlier).
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
AmcorAMCR$42.35-0.26%
ALL
The company said Allstate's net income applicable to common shareholders for Q3 2026 was $2.1 billion ($8.03 per diluted share), and adjusted net income was $2.5 billion ($9.76 per diluted share). Net income applicable to common shareholders was $3.7 billion and adjusted net income was $3.0 billion in the prior-year period.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
AllstateALL$267+0.09%
CPAY
The company said its Q3 2026 revenue rose to $1,381.9 million from $1,172.5 million a year earlier, up 18%, and net income attributable to Corpay increased 36% to $378.4 million.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
CorpayCPAY$429.84-1.02%
FIS
The company said the estimated fair value of its Banking reporting unit, which had goodwill of $19.9 billion, exceeded its carrying amount by approximately 7% as of September 30, 2026, so it recorded no goodwill impairment charge. The Capital Markets reporting unit, which had goodwill of $5.1 billion, exceeded its carrying amount by more than 50%.
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Fidelity National Information ServicesFIS$25.83-0.42%
FICO
The company said revenue for the fourth quarter of fiscal 2026 Q4, ended September 30, was $657.0 million, up 27% from $515.8 million in the year-earlier period.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Fair IsaacFICO$694.31+2.46%
PRU
The company said the suspension of new sales at Prudential of Japan reduced Japan Businesses' pre-tax adjusted operating income by an estimated $375 million in 2026 through January–September. It estimated that if the suspension is extended through January 31, 2027, the reduction would be about $500 million for 2026 and $500 to $550 million for 2027.
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Prudential FinancialPRU$117.73-2.14%
TRMB
Trimble said its annualized recurring revenue (ARR) for Q3 2026 was $2.6 billion, up 11% year over year, and that organic ARR growth, excluding the effects of foreign currency, acquisitions, and divestitures, was 10%.
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
TrimbleTRMB$50.65-2.58%
MRK
The company said global sales were $18.1 billion in Q3 2026, and U.S. sales were $51.0 billion in January–September, each up 5% from the year-earlier period. It said the oncology, cardiometabolic, respiratory and specialty franchises and animal health were the main drivers, while the vaccines and infectious diseases franchise declined.
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
MerckMRK$133.72+0.69%
ABT
The company said total net sales rose 14.8% in Q3 2026 excluding the impact of foreign exchange. It attributed the increase to the acquisition of Exact Sciences Corporation and high single-digit growth in Medical Devices and Established Pharmaceutical Products.
US filing analysisUS10-Q · Quarterly reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Abbott LaboratoriesABT$103-0.84%
FCX
FCX said its Board of Directors approved a $4.5 billion expansion and modernization program for the wholly owned Bagdad copper and molybdenum operation in northwest Arizona, according to a press release dated November 4, 2026.
US filing analysisUS8-K · Current reportPublished Nov 4, 2026 (UTC)SEC filing date Nov 4, 2026
Freeport-McMoRanFCX$45.99-6.37%
These reports are reference information based on public facts such as filings and prices. They do not recommend buying or selling any security.